The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
Abstract
Purpose: Fibroblast growth factor receptor 3 (FGFR3) mutations were recently found at a high frequency in well-differentiated urothelial cell carcinoma (UCC). We investigated the relationship between FGFR3 status and three molecular markers (MIB-1, P53, and P27 kip1) associated with worse prognosis and determined the reproducibility of pathologic grade and molecular variables. Patients and Methods: In this multicenter study, we included 286 patients with primary (first diagnosis) UCC. The histologic slides were reviewed. FGFR3 status was examined by polymerase chain reaction–single strand conformation polymorphism and sequencing. Expression levels of MIB-1, P53, and P27 kip1 were determined by immunohistochemistry. Mean follow-up was 5.5 years (range, 0.4 to 18.4 years). Results: FGFR3 mutations were detected in 172 (60%) of 286 UCCs. Grade 1 tumors had an FGFR3 mutation in 88% of patient samples and grade 3 tumors in 16% of patient samples. Conversely, aberrant expression patterns of MIB-1, P53, and P27 kip1 were seen in 5%, 2%, and 3% of grade 1 tumors and in 85%, 60%, and 56% of grade 3 tumors, respectively. In multivariate analysis with recurrence rate, progression, and disease-specific survival as end points, the combination of FGFR3 and MIB-1 proved independently significant in all three cases. By using these two molecular markers, three molecular grades (mGs) could be identified: mG1 (mutation; normal expression), favorable prognosis; mG2 (two remaining combinations), intermediate prognosis; and mG3 (no mutation; high expression), poor prognosis. The molecular variables were more reproducible than pathologic grade (85% to 100% v 47% to 61%). Conclusion: The FGFR3 mutation represents the favorable molecular pathway of UCC. Molecular grading provides a new, simple, and highly reproducible tool for clinical decision making in UCC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Estimates of the worldwide incidence of eighteen major cancers in 1985
Parkin, D. M., Pisani, P., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540413 · Cited by 1,638
Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199812000-00001 · Cited by 1,578
Structural and Functional Diversity in the FGf Receptor Multigene Family
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60821-0 · Cited by 1,250
TNM classification of malignant tumors, fifth edition (1997)
Sobin, L. H., & Fleming, I. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971101)80:9<1803::aid-cncr16>3.0.co;2-9 · Cited by 999
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Self-citationTwo molecular pathways to transitional cell carcinoma of the bladder.
Spruck, C., Ohneseit, P. F., Gonzalez‐Zulueta, M., Esrig, D., Miyao, N., Tsai, Y., Lerner, S. P., Schmütte, C., Yang, A. S., & Cote, R. (1994) · PubMed · Cited by 680
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Methods for Genotyping Single Nucleotide Polymorphisms
Kwok, P.-Y. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.235 · Cited by 580
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Self-citationVajo, Z., Francomano, C. A., & Wilkin, D. J. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0387 · Cited by 350
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
STEIN, J. P., GROSSFELD, G. D., GINSBERG, D. A., ESRIG, D., FREEMAN, J. A., FIGUEROA, A. J., SKINNER, D. G., & COTE, R. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62747-2 · Cited by 271
Allelotype of human bladder cancer.
Knowles, M. A., Elder, P. A., Williamson, M. P., Cairns, J. P., Shaw, M. E., & Law, M. G. (1994) · PubMed · Cited by 262
Bellus, G. A., Spector, E. B., Speiser, P. W., Weaver, C. A., Garber, A. T., Bryke, C. R., Israel, J., Rosengren, S. S., Webster, M. K., Donoghue, D. J., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/316892 · Cited by 174
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index
Allard, J., Bernard, B., Fradet, Y., & Têtu (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00628.x · Cited by 145
Partial allelotype of carcinoma in situ of the human bladder.
Rosin, M. P., Cairns, P., Epstein, J. I., Schoenberg, M., & Sidransky, D. (1995) · PubMed · Cited by 141
The genetics of transitional cell carcinoma: progress and potential clinical application
Knowles, M. A. (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00217.x · Cited by 137
Czerniak, B. A., Chaturvedi, V., Li, L., Hodges, S., Johnston, D. A., Ro, J. Y., Luthra, R., Logothetis, C. J., von Eschenbach, A. C., Grossman, H. B., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202385 · Cited by 127
Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa).
Zhao, J., Richter, J., Wagner, U., Roth, B., Schraml, P., Zellweger, T., Ackermann, D., Schmid, U., Moch, H., Mihatsch, M. J., et al. (1999) · PubMed · Cited by 110
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
Sibley, K., Heavens, D., & Knowles, M. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204110 · Cited by 108
Pfister, C., Moore, L., Allard, P., LaRue, H., Lacombe, L., Têtu, B., Meyer, F., & Fradet, Y. (1999) · PubMed · Cited by 95
Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis, on p27Kip1
Korkolopoulou, P. A., Christodoulou, P., Konstantinidou, A. E., Thomas-Tsagli, E., Kapralos, P., & Davaris, P. (2000) · Human Pathology · doi:10.1053/hupa.2000.8227 · Cited by 93
McShane, L., Aamodt, R. M., Cordon‐Cardo, C., Cote, R., Faraggi, D., Fradet, Y., Hb, G., Peng, A., Se, T., & Waldman, F. (2000) · PubMed · Cited by 93
Molecular evolution of multiple recurrent cancers of the bladder
van Tilborg, A. A. G. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.2973 · Cited by 91
Sgambato, A., Migaldi, M., Faraglia, B., Garagnani, L., Romano, G. D., Gaetani, C. D., Ferrari, P., Capelli, G., Trentini, G. P., & Cittadini, A. R. M. (1999) · PubMed · Cited by 82
Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy
Cordon‐Cardo, C., Côté, R. J., & Sauter, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169338 · Cited by 78
Webster, M. K., & Donoghue, D. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5739 · Cited by 65
Intravesical therapy for bladder cancer
Kamat, A. M., & Lamm, D. L. (2000) · Urology · doi:10.1016/s0090-4295(99)00463-x · Cited by 60
FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
Fracchiolla, N., Luminari, S., Baldini, L., Lombardi, L., Maiolo, A., & Neri, A. (1998) · Blood · doi:10.1182/blood.v92.8.2987 · Cited by 40
Wu, R., Connolly, D., Ngelangel, C., Bosch, F., Muñoz, N., & Cho, K. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203934 · Cited by 37
Cited by
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.028 · Cited by 1,916
A Molecular Taxonomy for Urothelial Carcinoma
Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Fernö, M., Ringnér, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0077-t · Cited by 944
Advances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
Hedegaard, J., Lamy, P., Nordentoft, I., Algaba, F., Høyer, S., Ulhøi, B. P., Vang, S., Reinert, T., Hermann, G. G., Mogensen, K., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.004 · Cited by 639
Self-citationFibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Metadata
- Authors
- van Rhijn, B. W. G., Vis, A. N., van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C. M., Chopin, D. K., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-05-15
- Volume
- 21
- Issue
- 10
- Pages
- 1912-1921
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099900006
- Cited by
- 322
- References
- 31
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.